A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Status:
Completed
Trial end date:
2011-03-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of subcutaneous (under
the skin) administration of anti-interleukin-6 monoclonal antibody (CNTO 136) in reducing
signs and symptoms of participants with active rheumatoid arthritis (RA) with methotrexate
(MTX) therapy.